ecrin-mdr-crcClinical2023IPD Sharing (as of October 2023): NoMetastatic Colorectal CancerSolid TumorGastric CancerAdvanced Solid TumorSolid Tumor, AdultNeoplasmsHepatocellular CarcinomaMetastatic Colorectal CancerSolid TumorGastric CancerAdvanced Solid TumorSolid Tumor, AdultNeoplasmsHepatocellular CarcinomaInterventionalhttps://newmdr.ecrin.org/Study/108696South Korea10Antineoplastic AgentsImmuno Modulating AgentsAngiogenesis Modulating AgentsAngiogenesis InhibitorsECRIN MDRRecruitingfalsePhase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating AgentThis clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have progressed after standard of care. PB101 may stop the growth of tumor cells by blocking blood flow to the tumor and modulating the tumor microenvironment.2023-10-15108696NCT06075849